Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Cancer

Why tumours eat tryptophan

Nature volume 478, pages 192–194 (2011)Cite this article

Subjects

Tumours increase their consumption of the amino acid tryptophan to evade immune control. But how does this work? A study shows that the main product of this consumption binds to a receptor involved in the immune system. See Article p.197

There is mounting evidence that fast-growing 'progressive' cancers occur because of a failure of the immune system to maintain control over budding tumours. The ability of cancers to escape immune responses is therefore attracting increasing attention, with numerous studies now pointing, perhaps surprisingly, to the consumption of the amino acid tryptophan as a critical factor in progressive cancer. On page 197 of this issue, Opitz et al.1 advance the field with their finding that many cancers upregulate a liver enzyme, tryptophan dioxygenase, to drive tryptophan consumption. What's more, the authors find that the primary product of this process, kynurenine, is an endogenous ligand for the aryl hydrocarbon receptor, which mediates invasive tumour growth. This second finding links the fields of toxicology, immunology and cancer biology in new ways, and may help to explain how elevated tryptophan consumption helps tumours to overcome immune barriers to cancer progression.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The kynurenine pathway of cancer invasion and immune escape.

References

  1. Opitz, C. A. et al. Nature 478, 197–203 (2011).

    Article  ADS  CAS  Google Scholar 

  2. Schreiber, R. D., Old, L. J. & Smyth, M. J. Science 331, 1565–1570 (2011).

    Article  ADS  CAS  Google Scholar 

  3. Munn, D. H. & Mellor, A. L. J. Clin. Invest. 117, 1147–1154 (2007).

    Article  CAS  Google Scholar 

  4. Prendergast, G. C. Oncogene 27, 3889–3900 (2008).

    Article  CAS  Google Scholar 

  5. Mellor, A. L. & Munn, D. H. Nature Rev. Immunol. 8, 74–80 (2008).

    Article  CAS  Google Scholar 

  6. Fallarino, F., Gizzi, S., Mosci, P., Grohmann, U. & Puccetti, P. Curr. Drug Metab. 8, 209–216 (2007).

    Article  CAS  Google Scholar 

  7. Katz, J. B., Muller, A. J. & Prendergast, G. C. Immunol. Rev. 222, 206–221 (2008).

    Article  CAS  Google Scholar 

  8. Uyttenhove, C. et al. Nature Med. 9, 1269–1274 (2003).

    Article  CAS  Google Scholar 

  9. Muller, A. J., Mandik-Nayak, L. & Prendergast, G. C. Immunotherapy 2, 293–297 (2010).

    Article  CAS  Google Scholar 

  10. Muller, A. J. et al. Proc. Natl Acad. Sci. USA 105, 17073–17078 (2008).

    Article  ADS  CAS  Google Scholar 

  11. Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E. & Prendergast, G. C. Nature Med. 11, 312–319 (2005).

    Article  CAS  Google Scholar 

  12. Balachandran, V. P. et al. Nature Med. 17, 1094–1100 (2011).

    Article  CAS  Google Scholar 

  13. Mezrich, J. D. et al. J. Immunol. 185, 3190–3198 (2010).

    Article  CAS  Google Scholar 

  14. Stevens, E. A., Mezrich, J. D. & Bradfield, C. A. Immunology 127, 299–311 (2009).

    Article  CAS  Google Scholar 

  15. Prendergast, G. C., Metz, R. & Muller, A. J. Am. J. Pathol. 176, 2082–2087 (2010).

    Article  CAS  Google Scholar 

  16. Vogel, C. F. A., Goth, S. R., Dong, B., Pessah, I. N. & Matsumura, F. Biochem. Biophys. Res. Commun. 375, 331–335 (2008).

    Article  CAS  Google Scholar 

  17. Nguyen, N. T. et al. Proc. Natl Acad. Sci. USA 107, 19961–19966 (2010).

    Article  ADS  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. George C. Prendergast is in the Lankenau Institute for Medical Research, Wynnewood, Pennsylvania 19096, USA.,

    George C. Prendergast

Authors
  1. George C. Prendergast
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George C. Prendergast.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Prendergast, G. Why tumours eat tryptophan. Nature 478, 192–194 (2011). https://doi.org/10.1038/478192a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/478192a

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer